On October 29, coinciding with World Psoriasis Day, FANGZHOU JIANKE (06086) and FOSUN PHARMA (02196) held a strategic cooperation signing ceremony in Shanghai. Dr. Xie Fangmin, Founder, Chairman, and CEO of FANGZHOU JIANKE, along with Li Mei, Co-CEO of FOSUN PHARMA’s Domestic Marketing Platform, and Huang Jiaguo, Head of the New Retail Division, formalized the partnership.
The collaboration aims to deepen synergy in "AI + chronic disease management," creating a benchmark digital project to unlock the full potential of chronic disease ecosystems. The partnership will initially focus on autoimmune diseases like psoriasis, integrating AI-driven academic research, public education, and digital marketing to enhance disease awareness, intervention, and long-term care.
Psoriasis, a chronic, recurrent, and inflammatory condition, demands standardized long-term management. Traditional approaches often struggle with low patient adherence, inadequate follow-ups, and lack of personalized care. However, AI-powered solutions now enable precise assessments, tailored treatments, and continuous monitoring throughout the disease lifecycle.
FOSUN PHARMA will contribute its commercialization expertise and innovative psoriasis treatment Otezla® (apremilast tablets), alongside professional medical knowledge. Meanwhile, FANGZHOU JIANKE will leverage its proprietary XingShi Medical AI model and "AI + H2H (Hospital To Home)" smart healthcare ecosystem to optimize psoriasis management.
Key initiatives include AI-powered health assistants offering personalized recovery guidance, 24/7 medication consultations, and seamless connections to medical advisors for complex cases—ensuring scientific and safe disease management.
Li Mei, Co-CEO of FOSUN PHARMA’s Domestic Marketing Platform, stated, "Our shared vision with FANGZHOU JIANKE in chronic disease management aligns perfectly. By combining our psoriasis innovations with their AI + H2H ecosystem, we aim to establish a systematic care framework for patients."
Dr. Xie Fangmin added, "This partnership marks a milestone in our AI strategy, transitioning from capability-building to value creation with industry leaders. Together, we’ll pioneer an AI-driven psoriasis management model and expand it to broader disease areas."
Following the signing, FANGZHOU JIANKE launched its "AI + Psoriasis Management" awareness week, featuring AI-enhanced livestreams that attracted over a million viewers. The campaign employs AI to tailor content, optimize engagement, and extend one-time education into sustained, interactive follow-ups—transforming health communication into a patient-centric, data-driven experience.
This collaboration sets the stage for further digital innovation in chronic disease management. With flagship projects like AI + weight management and AI + psoriasis, FANGZHOU JIANKE is accelerating its "AI +" ecosystem to support Healthy China initiatives.